Current Report Filing (8-k)
01 August 2019 - 6:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
July 25, 2019
Bionik
Laboratories Corp.
(Exact Name
of Registrant as Specified in Its Charter)
Delaware
|
|
000-54717
|
|
27-1340346
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: (416) 640-7887
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol
|
Name
of each exchange on which registered
|
Not applicable
|
Not applicable
|
Not applicable
|
|
Item
1.01
|
Entry
Into A Material Agreement.
|
The information set forth in Item 2.03
is incorporated by reference into this Item 1.01.
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
of a Registrant
|
On July 25, 2019, an investor (the “Lender”)
of Bionik Laboratories Corp. (the “Company”) subscribed for a convertible promissory note (the “Note”)
and loaned to the Company an aggregate of $250,000 (the “Loan”). The Loan represent an additional tranche borrowed
pursuant to an up to $9,000,000 convertible note offering (the “Offering”), for total borrowed principal through July
25, 2019 of $4,260,000.
The Company intends to use the net proceeds,
after payment of fees and expenses, from the Loan for the Company’s working capital and general corporate purposes.
The Note bears interest at a fixed rate
of 1% per month, computed based on a 360-day year of twelve 30-day months and will be payable, along with the principal amount,
on the earlier of (the “Maturity Date”): (a) March 30, 2020 and (b) the consummation of the Offering, provided that
the Company raises in one or more tranches aggregate gross proceeds of no less than US$9,000,000 (“Qualified Financing”).
The Note will be convertible into equity
of the Company upon the following events on the following terms:
|
·
|
On the Maturity Date without any action
on the part of the Lender, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares
of common stock at a conversion price of US$6.80 per share (the “Conversion Price”).
|
|
·
|
Upon a change of control transaction prior
to the Maturity Date, the outstanding principal and accrued and unpaid interest under the Note would, at the election of the holders
of a majority of the outstanding principal of the loans under the Offering, be either (i) payable upon demand as of the closing
of such change of control transaction or (ii) convertible into shares of the Company’s common stock immediately prior to
such change of control transaction at a price per share equal to the lesser of (x) the Conversion Price, or (y) the per share consideration
to be received by the holders of the common stock in such change of control transaction.
|
The Note contains customary events of default,
which, if uncured, entitle the Lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid
interest on, his Note.
The foregoing is a brief description of
the subscription of the Note and the terms of the Note and is qualified in its entirety by reference to the full text of the form
of Subscription Agreement and the form of the Note, the forms of which are included as Exhibits 10.1 and 10.2, respectively, to
the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 17, 2019, each of which
are incorporated herein by reference.
|
Item
3.02
|
Unregistered
Sales of Equity Securities.
|
The disclosure set forth above in Item
2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. The Note and,
unless subsequently registered, the shares underlying the Note, will be issued in reliance on the exemption from registration provided
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), Regulation D promulgated thereunder
and/or Regulation S under the Securities Act.
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On July 26, 2019, the Board of Directors
(the “Board”) of the Company approved the grant of 115,759 stock options to Eric Dusseux, the Chief Executive Officer
and a director of the Company. The options terminate on the seven-year anniversary of the grant date and vest and become exercisable
as follows: (i) 19,293 shares on each of September 1, 2019, September 1, 2020 and September 1, 2021; and (ii) 19,293 shares on
September 1, 2019, 19,293 shares on September 1, 2020, and 19,294 shares on September 1, 2021 based on Dr. Dusseux's achievement
of annual performance goals to be established by the Compensation Committee of the Board of Directors in consultation with Dr.
Dusseux. The extent to which each separate performance tranche becomes vested shall be determined by reference to the performance
targets set for that performance period.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: July 31, 2019
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
By:
|
/s/ Leslie Markow
|
|
Name:
|
Leslie Markow
|
|
Title:
|
Chief Financial Officer
|
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bionik Laboratories Corporation (CE) (OTCMarkets): 0 recent articles
More Bionik Laboratories Corp. News Articles